Last reviewed · How we verify
CHF 1535 100/6 NEXT DPI® 2 months
CHF 1535 is a fixed-dose combination of beclomethasone dipropionate and formoterol fumarate delivered via a dry powder inhaler for maintenance treatment of asthma and COPD.
CHF 1535 is a fixed-dose combination of beclomethasone dipropionate and formoterol fumarate delivered via a dry powder inhaler for maintenance treatment of asthma and COPD. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | CHF 1535 100/6 NEXT DPI® 2 months |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination |
| Target | Glucocorticoid receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone is an inhaled corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 agonist that provides bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects to improve airflow and reduce respiratory symptoms in obstructive airway diseases.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF 1535 100/6 NEXT DPI® 2 months CI brief — competitive landscape report
- CHF 1535 100/6 NEXT DPI® 2 months updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI